查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602117

生长抑制素类似物市场：按类型、按应用分类 - 全球预测 2025-2030

Somatostatin Analogs Market by Type (Lanreotide, Octreotide, Pasireotide), Application (Acromegaly, Neuroendocrine Tumors) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

生长抑制素类似物市场2023年估值为68亿美元，预计2024年将达到74.9亿美元，复合年增长率为10.32%，预计到2030年将达到135.2亿美元。

生长抑制素类似物是天然荷尔蒙生长抑制素的合成版本，主要用于医疗环境中治疗肢端肥大症、神经内分泌肿瘤和某些胃肠道疾病等疾病。这些类似物的需求是因为它们能够调节内分泌系统并抑制各种辅助荷尔蒙的分泌，这使得它们在治疗荷尔蒙分泌肿瘤中至关重要。生长抑制素类似物在肿瘤学和内分泌学中具有重要应用，对于优化荷尔蒙调节至关重要的患者预后至关重要。最终用途广泛，包括医院、专科诊所和研究机构。由于给药系统的技术进步、个人化医疗的趋势以及全球目标疾病盛行率的增加，该市场有望成长。影响成长的主要因素包括老化社会的人口变化以及疾病早期诊断和管理意识的提高。

主要市场统计
基准年[2023] 68亿美元
预测年份 [2024] 74.9亿美元
预测年份 [2030] 135.2亿美元
复合年增长率（%） 10.32%

药物配方和生长抑制素类似物缓释变异体的持续创新凸显了新的商机，这些创新有望改善患者的依从性和治疗结果。生物相似药的出现也提供了具有成本效益的解决方案并扩大了治疗的机会。然而，治疗成本上升、严格监管以及长期使用潜在副作用等挑战正在阻碍市场成长。药物传递的创新将在提高药物生物有效性、开发经皮贴片和植入装置等新型输送机制以及透过可能将精准医疗与人工智慧相结合来提高治疗准确性等领域取得进展。

瞄准这一市场的公司可能会受益于投资下一代配方的研发或与生技公司合作。监管合规性和对专利格局的了解对于保持竞争优势至关重要。由于市场受到专利到期和生物相似药进入的影响，保持产品创新和多样化至关重要。市场竞争仍然激烈，跨国製药巨头和新兴生物技术公司都专注于利基治疗领域，推动市场发展。

市场动态：揭示快速发展的生长抑制素类似物市场的关键市场洞察

生长抑制素类似物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 库欣氏症候群、肢端肥大症和其他相关疾病的发生率增加
    • 全球罕见疾病药物研发支出
    • 对罕见疾病患者有利的政府政策和製度
  • 市场限制因素
    • 由于大量未确诊患者导致意识下降
  • 市场机会
    • 新药上市的研发进展
    • 製药公司与研究公司的策略联盟
  • 市场挑战
    • 肢端肥大症等疾病的替代治疗方法的可用性

波特的五力：驾驭生长抑制素类似物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生长抑制素类似物市场的外在影响

外部宏观环境因素在塑造生长抑制素类似物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解生长抑制素类似物市场的竞争格局

对生长抑制素类似物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生长抑制素类似物市场供应商的绩效评估

FPNV 定位矩阵是评估生长抑制素类似物市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分了供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 库欣氏症候群、肢端肥大症和其他相关疾病的发生率增加
      • 全球正在投入巨额资金来开发治疗罕见疾病的药物。
      • 对罕见疾病患者有利的政府政策和製度
    • 抑制因素
      • 由于意识下降，未确诊患者的数量正在增加。
    • 机会
      • 持续进行新药发布的研发活动
      • 製药公司与研究公司之间的策略合作
    • 任务
      • 肢端肥大症等疾病的替代治疗方法的可用性
  • 市场区隔分析
    • 类型：Octreotide因其安全性和有效性而越来越受到青睐
    • 用途：利用生长抑制素类似物治疗肢端肥大症，因为其效力高且半衰期长。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章生长抑制素类似物市场：依类型

  • Lanreotide
  • Octreotide
  • 蝶形科

第七章生长抑制素类似物市场：依应用

  • 肢端肥大症
  • 神经内分泌肿瘤

第八章美洲生长抑制素类似物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区生长抑制素类似物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲生长抑制素类似物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA 已选择 RayzeBio 参与第一个 CDRP 计划，以加速 GEP-NET 上 RYZ101 的商业生产准备。
    • Ipsen 宣布投资 Somatulin Autogel/Somatulin Depot (Lanreotide) 新型电子自动注射器，旨在改善病患体验
    • 欧盟委员会核准mycapsa 用于治疗肢端肥大症

公司名单

  • Viatris Inc.
  • Wockhardt Ltd.
  • Bachem AG
  • Novartis AG
  • Hybio Pharmaceutical Co., Ltd.
  • Fresenius SE & Co. KGaA
  • MedKoo Biosciences, Inc.
  • Recordati Rare Diseases, Inc.
  • Dauntless Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • Ipsen Pharma
  • CVS Health Corporation
  • Abbiotec, Inc.
  • Peptron, Inc.
  • Camurus AB
  • Advanz Pharma Corp.
  • Crinetics Pharmaceuticals, Inc.
  • Pharmascience Inc.
  • Biodexa Pharmaceuticals PLC
  • Cipla Limited
  • Amryt Pharma PLC by Chiesi Farmaceutici SpA
  • Teijin Limited
  • Sun Pharmaceutical Industries Limited
Product Code: MRR-2214614773A1

The Somatostatin Analogs Market was valued at USD 6.80 billion in 2023, expected to reach USD 7.49 billion in 2024, and is projected to grow at a CAGR of 10.32%, to USD 13.52 billion by 2030.

Somatostatin analogs are synthetic versions of the naturally occurring hormone somatostatin, utilized primarily in medical settings to manage diseases such as acromegaly, neuroendocrine tumors, and certain gastrointestinal disorders. The necessity of these analogs stems from their ability to regulate the endocrine system and inhibit the secretion of various secondary hormones, making them pivotal in treating hormone-secreting tumors. With applications primarily in oncology and endocrinology, somatostatin analogs are indispensable in optimizing patient outcomes where hormone regulation is crucial. End-use scope spans across hospitals, specialty clinics, and research institutions. The market is poised for growth due to technological advancements in drug delivery systems, personalized medicine trends, and an increasing global prevalence of target diseases. Key factors influencing growth include demographic shifts towards an aging population and rising awareness about early disease diagnosis and management.

KEY MARKET STATISTICS
Base Year [2023] USD 6.80 billion
Estimated Year [2024] USD 7.49 billion
Forecast Year [2030] USD 13.52 billion
CAGR (%) 10.32%

Emerging opportunities are highlighted by ongoing innovations in drug formulation and extended-release variants of somatostatin analogs, which promise better patient compliance and outcomes. The advent of biosimilars also offers cost-effective solutions, widening access to treatments. However, market growth is challenged by factors such as high treatment costs, stringent regulatory pathways, and potential side effects associated with long-term use. Innovation can thrive in areas such as enhancing drug bioavailability, developing novel delivery mechanisms like transdermal patches or implantable devices, and integrating AI-driven precision medicine to tailor treatments more accurately.

For businesses aiming to capitalize on this market, investing in R&D for next-gen drug formulations and securing partnerships with biotech companies can be advantageous. Regulatory compliance and navigating patent landscapes are critical to maintaining competitive advantage. As the market is shaped by patent expirations and the entrance of biosimilars, maintaining innovation and diversification in product offerings will be essential. The nature of the market remains highly competitive, driven by both multinational pharmaceutical giants and emerging biotech firms focusing on niche therapeutic areas.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Somatostatin Analogs Market

The Somatostatin Analogs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing Incidence of Cushing Syndrome, Acromegaly and Other Associated Diseases
    • Extensive Spending on Development of Drugs for Rare Diseases Globally
    • Favorable Government Policies and Schemes for Patients with Rare Diseases
  • Market Restraints
    • Reduced Awareness Resulting in a High Number of Undiagnosed Patients
  • Market Opportunities
    • Ongoing Research and Development Activities for the Launch of Novel Drug Therapeutics
    • Strategic Collaboration Among Pharmaceutical and Research Companies
  • Market Challenges
    • Availability of Alternative Treatment Methods for Diseases Such as Acromegaly

Porter's Five Forces: A Strategic Tool for Navigating the Somatostatin Analogs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Somatostatin Analogs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Somatostatin Analogs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Somatostatin Analogs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Somatostatin Analogs Market

A detailed market share analysis in the Somatostatin Analogs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Somatostatin Analogs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Somatostatin Analogs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Somatostatin Analogs Market, highlighting leading vendors and their innovative profiles. These include Viatris Inc., Wockhardt Ltd., Bachem AG, Novartis AG, Hybio Pharmaceutical Co., Ltd., Fresenius SE & Co. KGaA, MedKoo Biosciences, Inc., Recordati Rare Diseases, Inc., Dauntless Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Ipsen Pharma, CVS Health Corporation, Abbiotec, Inc., Peptron, Inc., Camurus AB, Advanz Pharma Corp., Crinetics Pharmaceuticals, Inc., Pharmascience Inc., Biodexa Pharmaceuticals PLC, Cipla Limited, Amryt Pharma PLC by Chiesi Farmaceutici S.p.A., Teijin Limited, and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Somatostatin Analogs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Lanreotide, Octreotide, and Pasireotide.
  • Based on Application, market is studied across Acromegaly and Neuroendocrine Tumors.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Incidence of Cushing Syndrome, Acromegaly and Other Associated Diseases
      • 5.1.1.2. Extensive Spending on Development of Drugs for Rare Diseases Globally
      • 5.1.1.3. Favorable Government Policies and Schemes for Patients with Rare Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Reduced Awareness Resulting in a High Number of Undiagnosed Patients
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Research and Development Activities for the Launch of Novel Drug Therapeutics
      • 5.1.3.2. Strategic Collaboration Among Pharmaceutical and Research Companies
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of Alternative Treatment Methods for Diseases Such as Acromegaly
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing preference for octreotide due to its safety and efficacy
    • 5.2.2. Application: Utilization of somatostatin analogs for the treatment of acromegaly due to their greater potency and longer half life
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Somatostatin Analogs Market, by Type

  • 6.1. Introduction
  • 6.2. Lanreotide
  • 6.3. Octreotide
  • 6.4. Pasireotide

7. Somatostatin Analogs Market, by Application

  • 7.1. Introduction
  • 7.2. Acromegaly
  • 7.3. Neuroendocrine Tumors

8. Americas Somatostatin Analogs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Somatostatin Analogs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Somatostatin Analogs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs
    • 11.3.2. Ipsen announces investment in new electronic autoinjector for Somatuline Autogel / Somatuline Depot (lanreotide) designed to improve patient experience
    • 11.3.3. European Commission approves Mycapssa for the treatment of Acromegaly

Companies Mentioned

  • 1. Viatris Inc.
  • 2. Wockhardt Ltd.
  • 3. Bachem AG
  • 4. Novartis AG
  • 5. Hybio Pharmaceutical Co., Ltd.
  • 6. Fresenius SE & Co. KGaA
  • 7. MedKoo Biosciences, Inc.
  • 8. Recordati Rare Diseases, Inc.
  • 9. Dauntless Pharmaceuticals, Inc.
  • 10. Pfizer Inc.
  • 11. Merck KGaA
  • 12. Teva Pharmaceutical Industries Ltd.
  • 13. Ipsen Pharma
  • 14. CVS Health Corporation
  • 15. Abbiotec, Inc.
  • 16. Peptron, Inc.
  • 17. Camurus AB
  • 18. Advanz Pharma Corp.
  • 19. Crinetics Pharmaceuticals, Inc.
  • 20. Pharmascience Inc.
  • 21. Biodexa Pharmaceuticals PLC
  • 22. Cipla Limited
  • 23. Amryt Pharma PLC by Chiesi Farmaceutici S.p.A.
  • 24. Teijin Limited
  • 25. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. SOMATOSTATIN ANALOGS MARKET RESEARCH PROCESS
  • FIGURE 2. SOMATOSTATIN ANALOGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. SOMATOSTATIN ANALOGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. SOMATOSTATIN ANALOGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SOMATOSTATIN ANALOGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SOMATOSTATIN ANALOGS MARKET DYNAMICS
  • TABLE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ACROMEGALY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. SOMATOSTATIN ANALOGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. SOMATOSTATIN ANALOGS MARKET, FPNV POSITIONING MATRIX, 2023